Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism

James Peek, Mirjana Lilić, Daniel Montiel, Aleksandr Milshteyn, Ian Woodworth, John Biggins, Melinda A. Ternei, Paula Y. Calle, Michael M. Danziger, Thulasi Warrier, Kohta Saito, Nathaniel R. Braffman, Allison Fay, Michael S. Glickman, Seth A. Darst, Elizabeth A. Campbell, Sean F. BradyNature Communications 2018 · DOI

TL;DR

Researchers have discovered novel rifamycin-like compounds called kanglemycins (Kangs) from soil microbes that are effective against rifampicin-resistant bacteria. These Kangs work through a unique mechanism that bypasses common resistance pathways, offering a promising avenue for developing new antibiotics to combat drug-resistant infections like tuberculosis.

What Problem Does This Paper Address?

Rifampicin (Rif) is a cornerstone antibiotic for treating tuberculosis and other bacterial infections. However, its effectiveness is increasingly undermined by the rise of antibiotic resistance, particularly mutations in the bacterial RNA polymerase (RNAP) enzyme, the drug's target. This resistance is a major global health threat. The authors hypothesize that natural environments, like soil, might harbor bacteria that have evolved to produce antibiotic variants (congeners) capable of overcoming these resistance mechanisms. This study aims to discover and characterize such natural products and understand how they circumvent resistance.

Methods

The researchers employed a multi-pronged approach:

  • Metagenomic Screening: They screened DNA from thousands of soil samples using PCR to identify gene clusters responsible for producing rifamycin-like compounds. This involved targeting the AHBA synthase gene, a key enzyme in the biosynthesis of ansamycin natural products, including rifamycins.
  • Gene Cluster Characterization: Promising gene clusters were sequenced and analyzed to identify the enzymes involved in producing novel rifamycin congeners.
  • Compound Isolation and Structure Elucidation: Kanglemycins (Kangs A, V1, and V2) were isolated from bacterial cultures and their structures were determined using high-resolution mass spectrometry (HRMS) and various NMR techniques.
  • Antibacterial Assays: The in vitro and in vivo activity of Kangs was tested against various bacterial strains, including those with common rifampicin-resistance mutations in their RNAP.
  • Structural Biology: X-ray crystallography was used to determine the structures of RNAP bound to Rif and Kang A. This allowed for a detailed comparison of how these molecules interact with the target enzyme, especially in the context of resistance mutations.
  • Mechanistic Studies: In vitro transcription assays were performed to dissect the mechanism of action of Kangs, comparing it to that of Rif. This involved probing steps like promoter binding, substrate binding, and RNA synthesis.

Datasets

  • Soil Metagenomic DNA: DNA was extracted from approximately 1500 geographically and ecologically diverse soil samples.
  • Publicly Available Bacterial Genomes: Used for comparison during gene cluster analysis.
  • Cultured Bacterial Genome: One gene cluster was identified in the genome of a cultured bacterium.
  • Previously Characterized Rifamycin Gene Clusters: Used as references for phylogenetic analysis.

No new benchmark datasets were introduced; the focus was on discovering novel compounds from environmental samples.

Key Insights and Ideas

  • Nature's Solution to Resistance: Soil microbiomes are a rich source of novel antibiotic congeners that have evolved to overcome resistance mechanisms, offering a promising strategy for drug discovery.
  • Kanglemycins: A New Class of Rifamycins: The discovery of kanglemycins (Kangs) highlights a new family of rifamycin-like compounds with potent activity against rifampicin-resistant bacteria.
  • Distinct Mechanism of Action: Unlike Rif, which primarily blocks RNA translocation, Kangs interfere with the initial binding of nucleotide substrates to RNAP, a step upstream of Rif's action. This novel mechanism is key to their effectiveness against resistant strains.
  • Structural Basis for Efficacy: Unique structural features of Kangs, specifically the "K-sugar" and "K-acid" moieties, are responsible for their enhanced binding to RNAP and their ability to overcome resistance mutations.
  • Evolutionary Arms Race: The structural complexity and unique mechanisms of Kangs suggest they have evolved under selective pressure from rifampicin-resistant bacteria in their natural environment.

Key Results

  • Kangs A, V1, and V2 demonstrated potent in vitro and in vivo activity against bacterial strains carrying common rifampicin-resistance mutations in RNAP.
  • Kang V2 showed particularly high potency against a key rifampicin-resistant mutation (S447L in M. smegmatis RNAP, corresponding to S456L in M. tuberculosis).
  • X-ray crystallography revealed that while Kangs bind to a similar site as Rif, their unique K-sugar and K-acid groups form additional interactions with RNAP.
  • Mechanistic studies showed that Kangs inhibit both full-length transcript production and abortive transcripts, indicating an earlier intervention in the transcription process compared to Rif.
  • Specifically, the K-acid moiety of Kangs appears to interfere with the binding of initiating nucleotide substrates (iNTPs) to RNAP through electrostatic repulsion.

Limitations and Future Work

  • In Vivo Efficacy in Complex Models: While in vivo activity was shown in Sau strains, further testing in more complex models, particularly against Mycobacterium tuberculosis, would be valuable.
  • Specific RNAP Mutant Interactions: Detailed structural and mechanistic studies of Kang V1 and V2 with their most potent RNAP mutants are planned for future work.
  • Evolutionary Advantage: While activity against resistant strains suggests an evolutionary advantage, direct evidence for this in natural environments is still needed.
  • Broader Application of Metagenomics: The study suggests that this approach of mining soil microbiomes for antibiotic congeners could be applied to other antibiotic classes to uncover novel compounds that circumvent resistance.
  • Clinical Translation: The identified Kangs represent potential lead compounds, but significant further development would be required for them to become clinical therapeutics.

Summary updated

Abstract

Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (Rif<sup>R</sup>). As resistance mechanisms found in clinical settings may also occur in natural environments, here we postulated that bacteria could have evolved to produce rifamycin congeners active against clinically relevant resistance phenotypes. We survey soil metagenomes and identify a tailoring enzyme-rich family of gene clusters encoding biosynthesis of rifamycin congeners (kanglemycins, Kangs) with potent in vivo and in vitro activity against the most common clinically relevant Rif<sup>R</sup> mutations. Our structural and mechanistic analyses reveal the basis for Kang inhibition of Rif<sup>R</sup> RNAP. Unlike Rifs, Kangs function through a mechanism that includes interfering with 5'-initiating substrate binding. Our results suggest that examining soil microbiomes for new analogues of clinically used antibiotics may uncover metabolites capable of circumventing clinically important resistance mechanisms.
BibTeX
@inproceedings{peek2018rifamycin,
  author = {James Peek and Mirjana Lilić and Daniel Montiel and Aleksandr Milshteyn and Ian Woodworth and John Biggins and Melinda A. Ternei and Paula Y. Calle and Michael M. Danziger and Thulasi Warrier and Kohta Saito and Nathaniel R. Braffman and Allison Fay and Michael S. Glickman and Seth A. Darst and Elizabeth A. Campbell and Sean F. Brady},
  title = {{Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism}},
  booktitle = {Nature Communications},
  year = {2018},
  doi = {10.1038/s41467-018-06587-2},
}
Figure